Sign in
Taking peoplePhase 4

Alfacalcidol for high parathyroid hormone after gastric bypass surgery

Tests alfacalcidol for secondary hyperparathyroidism in adults after gastric bypass surgery.

Key facts

Who runs it
Academisch Ziekenhuis Leiden
Where
Netherlands5 sites in 1 countryChoose a country to see its sites
Registry title
Active vitamin D for secondary hyperparathyroidism after bariatric surgery: a multicenter randomized controlled trial (ActiVitD)
Status
Recruiting
Phase
Phase 4
People taking part
130 people, planned
Started
4 Nov 2024
Planned end
1 May 2026
Type of study
Interventional
Record updated
4 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who had Roux-en-Y gastric bypass surgery and now have secondary hyperparathyroidism. This means the parathyroid glands make too much hormone. The trial tests alfacalcidol, a form of active vitamin D.

Age
18 years or older
Sex
Men and women, both before and after menopause
Disease stage
Secondary hyperparathyroidism that started after Roux-en-Y gastric bypass surgery
Earlier treatment
Must have had Roux-en-Y gastric bypass surgery. Must be taking only standard supplements. People already on active treatment for osteoporosis cannot join.
Biomarker or test result
Vitamin D level must be sufficient (>50 nmol/l)

Main reasons for not taking part

  • Chronic kidney disease with eGFR < 60 ml/min
  • A second weight-loss operation after an earlier one
  • Long-term steroid use, or known inflammatory conditions such as rheumatoid arthritis
  • High calcium in the blood at screening
  • Active wish to become pregnant

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Men and both pre- and postmenopausal women who have had Roux-en-Y-gastric bypass surgery, aged 18 years or above, and present with secondary hyperparathyroidism after surgery, with a vitamin D sufficient state (>50 nmol/l), and only on standard supplementation, are included
  • Provide informed consent prior to any specific study procedure

Who cannot take part

  • Patients that are on chronic steroid use, for example for inflammatory conditions
  • Patients with known inflammatory conditions (i.e. rheumatoid arthritis)
  • Patients with chronic kidney disease defined as eGFR < 60 ml/min
  • Patients who are already on active treatment for osteoporosis before inclusion
  • Patients who had a bariatric intervention before and are re-operated
  • Patients that appear to have hypercalcemia on screening
  • Patients that have an active pregnancy wish

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To investigate the effect of alfacalcidol on the treatment of secondary hyperparathyroidism in patients after RYGB

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Active vitamin D for secondary hyperparathyroidism after bariatric surgery: a multicenter randomized controlled trial (ActiVitD)
Plain-language title
Alfacalcidol for high parathyroid hormone after gastric bypass surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
4 November 2024